YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
MediLink Therapeutics (Suzhou) Co., Ltd.
CSPC Megalith Biopharmaceutical Co.,Ltd.
Gilead Sciences
AstraZeneca
Sun Yat-sen University
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Japan Breast Cancer Research Group
Spanish Breast Cancer Research Group
Qilu Pharmaceutical Co., Ltd.
Shanghai Yizhong Pharmaceutical Co., Ltd.
Gilead Sciences
University of Ulm
Sun Yat-sen University
RemeGen Co., Ltd.
Byondis B.V.
Spanish Breast Cancer Research Group
Nektar Therapeutics
Gilead Sciences
Centre Hospitalier Universitaire de Besancon
Zhejiang Cancer Hospital
Sun Yat-sen University
Fudan University
Boehringer Ingelheim
Eisai Inc.
Tianjin Medical University Cancer Institute and Hospital
Novartis
Sun Yat-sen University
iOMEDICO AG
National Cancer Institute (NCI)
ChineseAMS
Dana-Farber Cancer Institute
Hellenic Oncology Research Group
Danish Breast Cancer Cooperative Group